ANEBULO PHARMACEUTICALS INC (ANEB) Stock Price, Quote, News and Overview
NASDAQ:ANEB - Nasdaq - US0345691036 - Common Stock - Currency: USD
ANEB Quote, Performance and Key Statistics
NASDAQ:ANEB (6/6/2025, 8:00:01 PM)
1.08
-0.05 (-4.17%)
The current stock price of ANEB is 1.08 USD. In the past month the price increased by 0.93%. In the past year, price decreased by -50.23%.
ANEB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.95 | 729.65B | ||
| JNJ | JOHNSON & JOHNSON | 15.43 | 373.01B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.79 | 331.61B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.2 | 233.10B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.56 | 225.96B | ||
| MRK | MERCK & CO. INC. | 10.14 | 198.30B | ||
| PFE | PFIZER INC | 7.27 | 132.75B | ||
| SNY | SANOFI-ADR | 11.34 | 122.83B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.52B | ||
| GSK | GSK PLC-SPON ADR | 9.24 | 83.49B | ||
| ZTS | ZOETIS INC | 28.27 | 75.76B | ||
| HLN | HALEON PLC-ADR | 22.59 | 49.81B |
Related stock screener links
About ANEB
Company Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Company Info
ANEBULO PHARMACEUTICALS INC
C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107
Lakeway TEXAS US
CEO: Daniel Schneeberger
Employees: 3
Phone: 17372035270
ANEBULO PHARMACEUTICALS INC / ANEB FAQ
What is the stock price of ANEBULO PHARMACEUTICALS INC today?
The current stock price of ANEB is 1.08 USD. The price decreased by -4.17% in the last trading session.
What is the ticker symbol for ANEBULO PHARMACEUTICALS INC stock?
The exchange symbol of ANEBULO PHARMACEUTICALS INC is ANEB and it is listed on the Nasdaq exchange.
On which exchange is ANEB stock listed?
ANEB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANEBULO PHARMACEUTICALS INC stock?
8 analysts have analysed ANEB and the average price target is 5.61 USD. This implies a price increase of 419.44% is expected in the next year compared to the current price of 1.08. Check the ANEBULO PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANEBULO PHARMACEUTICALS INC worth?
ANEBULO PHARMACEUTICALS INC (ANEB) has a market capitalization of 44.37M USD. This makes ANEB a Nano Cap stock.
How many employees does ANEBULO PHARMACEUTICALS INC have?
ANEBULO PHARMACEUTICALS INC (ANEB) currently has 3 employees.
What are the support and resistance levels for ANEBULO PHARMACEUTICALS INC (ANEB) stock?
ANEBULO PHARMACEUTICALS INC (ANEB) has a support level at 1 and a resistance level at 1.13. Check the full technical report for a detailed analysis of ANEB support and resistance levels.
Should I buy ANEBULO PHARMACEUTICALS INC (ANEB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANEB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANEB, evaluating the profitability, health, valuation and growth aspects
- ANEBULO PHARMACEUTICALS INC (ANEB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANEBULO PHARMACEUTICALS INC (ANEB) Sales and EPS estimates to see what analysts future expectations are.
- ANEBULO PHARMACEUTICALS INC (ANEB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANEBULO PHARMACEUTICALS INC (ANEB) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANEBULO PHARMACEUTICALS INC (ANEB) Stock Chart to make your own analysis
- ANEBULO PHARMACEUTICALS INC (ANEB) Latest news and press-releases to stay up to date.
Does ANEBULO PHARMACEUTICALS INC (ANEB) stock pay dividends?
ANEB does not pay a dividend.
When does ANEBULO PHARMACEUTICALS INC (ANEB) report earnings?
ANEBULO PHARMACEUTICALS INC (ANEB) will report earnings on 2025-09-23, after the market close.
What is the Price/Earnings (PE) ratio of ANEBULO PHARMACEUTICALS INC (ANEB)?
ANEBULO PHARMACEUTICALS INC (ANEB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is the Short Interest ratio of ANEBULO PHARMACEUTICALS INC (ANEB) stock?
The outstanding short interest for ANEBULO PHARMACEUTICALS INC (ANEB) is 0.14% of its float. Check the ownership tab for more information on the ANEB short interest.
ANEB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ANEB. When comparing the yearly performance of all stocks, ANEB is a bad performer in the overall market: 87.41% of all stocks are doing better.
ANEB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANEB. ANEB has a great financial health rating, but its profitability evaluates not so good.
ANEB Financial Highlights
Over the last trailing twelve months ANEB reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 29.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.89% | ||
| ROE | -57.12% | ||
| Debt/Equity | 0 |
ANEB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ANEB. The Buy consensus is the average rating of analysts ratings from 8 analysts.